Microviable Therapeutics announces €1.5 million investment

Preclinical stage biotechnology company Microviable Therapeutics SL has raised €1.5 million seed funding from private medical group, Inmunomet Intolerancia y Disbiosis SL.

Microviable will use the funding to enhance its therapeutic development platform and advance the pipeline to the clinical stage.

The company’s lead product, MVT-201, is a biological drug based on complete microbiota (HiPM^TM) for undisclosed targets.

The investment will enable Microviable to focus on its therapeutics while increasing its facilities and expanding the team.

Claudio Hidalgo Cantabrana, PhD, co-founder and CEO at Microviable, said:

“We are really excited for Microviable´s future and grateful for this opportunity to bring novel solutions to healthcare with the ultimate goal of improving the patients’ quality of life.

“We wanted a strategic partner that shares our vision of using microbiota-derived biological drugs to treat patients while providing smart capital, and Inmunomet fulfills all of our expectations.”

Inmunomet is a private medical group specialising in intolerances and gut dysbiosis related disorders.

With this investment, the group is ‘seeking to be part of Microviable´s growth being ahead on the development of novel solutions based on microbiota-derived biotherapeutic products.’

Microviable Therapeutics SL, spun out from the Spanish National Research Council in 2016, focuses on developing novel technologies and therapeutic products from the microbiota.

In March, the company announced that it had entered into a contractual agreement with BCD Bioscience to work on microbial fermentation and novel prebiotics to modulate the human gut microbiome.